纳米医药向铁灭,以克服抗癌治疗耐药性
Jing Cai1,2, Xiaoding Xu1,2, Phei Er Saw3,4
1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
Science China. Life sciences
|September 20, 2023
概括
瘤对治疗的耐药性是一个主要障碍,但铁亡 (依赖铁的细胞死亡) 提供了新的治疗策略. 铁灭菌纳米诱导剂在克服耐药性和提高瘤治疗有效性方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 纳米医学是一种纳米医学.
- 生物化学 生物化学
背景情况:
- 治疗耐药性是化疗,放射治疗和免疫治疗中的一个重大挑战,导致瘤复发和转移.
- 抵抗的机制包括抑制细胞死亡,耐药性,DNA修复和改变瘤微环境.
- 铁,一种依赖于铁和脂质过氧化的受调细胞死亡形式,已成为治疗耐药性的关键因素.
研究的目的:
- 详细介绍铁灭介导协同瘤治疗的设计,机制和治疗应用.
- 探索铁灭菌在克服治疗耐药性的作用.
- 讨论纳米医学的潜力与铁灭调节的结合,用于联合癌症治疗.
主要方法:
- 关于ferroptosis诱导剂及其在治疗耐药性中的作用的最新研究的综述.
- 分析ferroptosis纳米诱导机制,包括直接诱导ferroptosis和反调节.
- 讨论将铁与临床治疗相结合的协同治疗策略.
主要成果:
- 铁质死在瘤治疗耐药性方面起着至关重要的作用.
- 铁灭诱导剂,特别是纳米诱导剂,可以通过触发细胞死亡和反调节来逆转抵抗.
- 使用铁灭诱导剂的组合疗法显示出增强的抗瘤效果.
结论:
- Ferroptosis介导的协同疗法提供了一种有希望的方法来对抗瘤治疗耐药性.
- 针对ferroptosis的纳米医学策略具有改善癌症治疗结果的巨大潜力.
- 对ferroptosis调节和组合疗法的进一步研究对于临床转化至关重要.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Necrosis
4.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.6K
Electron Transport Chain: Complex I and II
14.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.4K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


